Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgically removed.
Checked against the public recordLast updated Dec 1, 2016 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Alliance for Clinical Trials in Oncology
- Interventions being studied
- Drug: carboplatin; Drug: paclitaxel; Radiation: radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) * Stage I, II, or III NSCLC that is unresectable due to tumor extent or other medical reasons * Measurable disease * Tumor must not exceed volume that would require radiation volumes greater than those allowed on this study * No more than blunting of the costophrenic angle on chest x-ray due to pleural effusions * No more than small effusions seen on chest CT scan only * No supraclavicular adenopathy PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-1 Life expectancy: * At least 12 weeks Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Total bilirubin no greater than 1.5 times upper limit of normal (ULN) OR * Direct bilirubin no greater than 1.5 times ULN * AST no greater than 3 times ULN Renal: * Creatinine clearance at least 40 mL/min Cardiovascular: * No New York Heart Association class III or IV heart disease Pulmonary: * FEV\_1 at least 1 L or 35% of predicted Other: * No grade 2 or greater peripheral neuropathy * No weight loss of 10% or more within the past 3 months * No uncontrolled infection * No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinoma (carcinoma in situ), or localized prostate cancer * No other severe underlying disease that would preclude study participation * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic: * No prior biologic therapy for NSCLC * No concurrent biologic therapy * No concurrent prophylactic filgrastim (G-CSF) Chemotherapy: * No prior chemotherapy for NSCLC * No other concurrent chemotherapy Endocrine therapy: * No prior endocrine therapy for NSCLC Radiotherapy: * No prior radiotherapy for NSCLC Surgery: * No prior surgery for NSCLC
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic ScottsdaleScottsdale, Arizona
- Mayo Clinic - JacksonvilleJacksonville, Florida
- McFarland Clinic, PCAmes, Iowa
- Mercy Capitol HospitalDes Moines, Iowa
- CCOP - Iowa Oncology Research AssociationDes Moines, Iowa
- John Stoddard Cancer Center at Iowa Methodist Medical CenterDes Moines, Iowa
- Medical Oncology and Hematology Associates at John Stoddard Cancer CenterDes Moines, Iowa
- Medical Oncology and Hematology Associates at Mercy Cancer CenterDes Moines, Iowa
- Mercy Cancer Center at Mercy Medical Center - Des MoinesDes Moines, Iowa
- John Stoddard Cancer Center at Iowa Lutheran HospitalDes Moines, Iowa
- Siouxland Hematology-Oncology Associates, LLPSioux City, Iowa
- Mercy Medical Center - Sioux CitySioux City, Iowa
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 1, 2016. Always confirm current availability with the study team.